Overview

Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension

Status:
Completed

Trial end date:
2009-04-01

Target enrollment:

Participant gender:

Summary

This study will compare the efficacy and safety of once daily dosing of aliskiren monotherapy to once daily dosing of aliskiren and hydrochlorothiazide combination therapy in patients with Stage II hypertension over a period of 12 weeks.

Phase:

Phase 3

Details

Lead Sponsor:

Novartis

Treatments:

Hydrochlorothiazide